Transcend Capital Advisors LLC Sells 66,050 Shares of Pfizer Inc. $PFE

Transcend Capital Advisors LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 53.4% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 57,536 shares of the biopharmaceutical company’s stock after selling 66,050 shares during the quarter. Transcend Capital Advisors LLC’s holdings in Pfizer were worth $1,395,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of PFE. Brighton Jones LLC lifted its position in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after acquiring an additional 618,117 shares during the period. Revolve Wealth Partners LLC raised its holdings in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 2,087 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Pfizer by 38.7% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,182,830 shares of the biopharmaceutical company’s stock worth $29,027,000 after buying an additional 330,019 shares in the last quarter. Verity Asset Management Inc. raised its holdings in shares of Pfizer by 108.0% during the 1st quarter. Verity Asset Management Inc. now owns 76,276 shares of the biopharmaceutical company’s stock worth $1,933,000 after buying an additional 39,608 shares in the last quarter. Finally, Amalgamated Bank raised its holdings in shares of Pfizer by 1.5% during the 1st quarter. Amalgamated Bank now owns 1,101,526 shares of the biopharmaceutical company’s stock worth $27,913,000 after buying an additional 16,085 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on PFE shares. UBS Group reissued a “neutral” rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Citigroup boosted their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Bank of America boosted their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Finally, Morgan Stanley lowered their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average price target of $28.13.

Pfizer Price Performance

Shares of PFE opened at $24.76 on Tuesday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $29.17. The business has a 50-day simple moving average of $24.86 and a two-hundred day simple moving average of $24.21. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The stock has a market cap of $140.75 billion, a PE ratio of 13.17, a PEG ratio of 0.82 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the prior year, the firm earned $0.60 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer’s dividend payout ratio is presently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.